Last reviewed · How we verify
Panitumumab and CPT-11
Panitumumab and CPT-11 is a Small molecule drug developed by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). It is currently in Phase 2 development.
At a glance
| Generic name | Panitumumab and CPT-11 |
|---|---|
| Sponsor | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma (PHASE2)
- Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (PHASE2)
- Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (PHASE2)
- Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (PHASE2)
- A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma (PHASE2)
- Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver (PHASE2)
- Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer (PHASE2)
- FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panitumumab and CPT-11 CI brief — competitive landscape report
- Panitumumab and CPT-11 updates RSS · CI watch RSS
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) portfolio CI
Frequently asked questions about Panitumumab and CPT-11
What is Panitumumab and CPT-11?
Panitumumab and CPT-11 is a Small molecule drug developed by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Who makes Panitumumab and CPT-11?
Panitumumab and CPT-11 is developed by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (see full Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) pipeline at /company/spanish-cooperative-group-for-the-treatment-of-digestive-tumours-ttd).
What development phase is Panitumumab and CPT-11 in?
Panitumumab and CPT-11 is in Phase 2.